Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$13.54MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Seth Lederman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Beta
- 1.75
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.62
Financials
Revenue
$13.54MNet Income
$-40.55MEBITDA
$-39.95MFree Cash Flow
$-42.83MEPS (diluted)
$-2.44Shares Outstanding (diluted)
16.64M+4158713.5%Operating Expenses
$55.38MCash & Debt
$176.23MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.11M | $-124.02M | $-14.57 |
| 2024 | $10.09M | $-130.04M | $-176.60 |
| 2023 | $7.77M | $-116.66M | $-6368.84 |
| 2022 | $0.00 | $-110.22M | $-811.68 |
| 2021 | $0.00 | $-92.29M | $-163968.00 |
| 2020 | $0.00 | $-50.46M | $-5056.00 |
| 2019 | $0.00 | $-28.62M | $-3866.00 |
| 2018 | $0.00 | $-29.36M | $-18064.62 |
| 2017 | $0.00 | $-21.12M | $-54023.02 |
| 2016 | $0.00 | $-38.84M | $-199189.74 |
| 2015 | $0.00 | $-48.05M | $-511212.77 |
| 2014 | $0.00 | $-27.62M | $-511407.41 |
| 2013 | $0.00 | $-10.88M | $-375310.34 |
| 2012 | $0.00 | $-9.4K | $-945000.00 |
Valuation
TNXPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-81.25%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·14d ago·Negative
…oximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38…
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.
View source ↗ - Newsmarketbeat.com·49d ago·Neutral
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Tonix Pharmaceuticals Q2 Earnings Call Highlights Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-2.45 per share
Typical surprise -15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-2.44 vs $-2.64beat
- Mon, May 11$-2.93 vs $-2.54miss
- Thu, Mar 12$-3.98 vs $-3.16miss
- Mon, Nov 10$-3.59 vs $-3.59beat
- Tue, Aug 12$-3.86 vs $-3.10miss
- Mon, May 12$-2.84 vs $-3.23beat
Estimates and results for TNXP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNXP officers and directors.
- Bought
- $569k
- Sold
- —
10 trades
0 trades
- Lederman Sethbought
- Bagger Richard Hbought
- Taylor Carolyn E.bought
- Lederman Sethbought
- Stillwell Richard Newcombbought
- Lederman Sethbought
- Lederman Sethbought
- Taylor Carolyn E.bought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TNXP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.